Congresses and Publications

RATIONALE 304: tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous non-small cell lung cancer (nsq-NSCLC) RATIONALE 307: phase 3 study of tislelizumab plus chemotherapy vs chemotherapy alone as first‑line treatment for advanced squamous non‑small cell lung cancer

Tislelizumab plus standard chemotherapy and health-related quality of life In patients with advanced squamous non-small cell lung cancer

ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM) Neoadjuvant tislelizumab or placebo plus platinum-based chemotherapy followed by adjuvant tislelizumab or placebo in patients with resectable non‑small cell lung cancer (NSCLC): a phase 3 trial in progress Phase 3 trial in progress: tislelizumab plus cisplatin/carboplatin and gemcitabine versus placebo plus cisplatin/carboplatin and gemcitabine in Chinese patients with advanced urothelial carcinoma Phase 3 trial in progress: tislelizumab vs placebo in combination with concurrent chemoradiotherapy (cCRT) in patients with localized esophageal squamous cell carcinoma (ESCC) Platinum-containing combination chemotherapy with or without tislelizumab as first-line therapy in patients with extensive-stage small cell lung cancer: A phase 3 trial in progress RATIONALE 304: tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous non-small cell lung cancer (nsq-NSCLC) RATIONALE 307: phase 3 study of tislelizumab plus chemotherapy vs chemotherapy alone as first‑line (1L) treatment for advanced squamous non‑small cell lung cancer (sq NSCLC) Tislelizumab + chemotherapy versus placebo + chemotherapy in Chinese patients with recurrent or metastatic nasopharyngeal cancer: a phase 3 trial-in-progress Tislelizumab in Chinese patients with non-small cell lung cancer (NSCLC) Tislelizumab plus standard chemotherapy and health-related quality of life In patients with advanced squamous non-small cell lung cancer Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88^WT) Waldenström macroglobulinemia (WM) Zanubrutinib (BGB-3111) in combination with rituximab in patients with relapsed/refractory non-Hodgkin lymphoma Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase 2, single-arm, multicenter, study

BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma Clinical benefit in biomarker-positive patients with locally advanced or metastatic solid tumors treated with the PARP 1/2 inhibitor pamiparib in combination with low-dose temozolomide

Investigation of PD-L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with VENTANA PD-L1 (SP263) assay and combined positive score (CPS) Phase 2 study of pamiparib in Chinese patients with advanced ovarian cancer Safety and efficacy of long-term exposure (LTE) to tislelizumab in Chinese patients with advanced solid tumors Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment in locally advanced/metastatic non-squamous NSCLC Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer

BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumors treated with the PARP 1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ) Investigation of PD-L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with VENTANA PD-L1 (SP263) assay and combined positive score (CPS) Phase 2 study of pamiparib in Chinese patients (pts) with advanced ovarian cancer (aOC) Safety and efficacy of long-term exposure (LTE) to tislelizumab in Chinese patients with advanced solid tumors Tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC (nsq-NSCLC) Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC)

BGB-10188, a highly selective PI3Kδ inhibitor with improved safety profile and superior anti-tumor activities in vivo Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior anti-tumour activities in haematological tumour models Preliminary safety and efficacy data of BGB-A333, an anti-PD-L1 monoclonal antibody, alone and in combination with tislelizumab in patients with advanced solid tumors RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors

BGB-10188, a highly selective PI3Kδ inhibitor with improved safety profile and superior anti-tumor activities in vivo Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior anti-tumor activities in haematological tumour models Preliminary safety and efficacy data of BGB-A333, an anti-PD-L1 monoclonal antibody, alone and in combination with tislelizumab in patients with advanced solid tumors RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors

ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia

Biomarker identification in relapsed/refractory non-germinal center B-cell-like diffuse large B-cell lymphoma treated with zanubrutinib Outcomes of relapsed/refractory MCL patients treated with zanubrutinib monotherapy in the second line and in later lines: a pooled analysis from 2 studies Phase 1/2 study of single-agent zanubrutinib in patients with relapsed/refractory marginal zone lymphoma Tislelizumab (BGB-A317) for relapsed/refractory extranodal NK/T-cell lymphoma: preliminary efficacy and safety results from a phase 2 study Tislelizumab (BGB-A317) for relapsed/refractory peripheral T-cell lymphoma: safety and efficacy results from a phase 2 study Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type Waldenstrom macroglobulinemia Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow‑up

ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrom macroglobulinemia (WM) Biomarker identification in relapsed/refractory non-germinal center B-cell like diffuse large B-cell lymphoma treated with zanubrutinib Outcomes of relapsed/refractory MCL patients treated with zanubrutinib monotherapy in the second line and in later lines: a pooled analysis from 2 studies Phase 1/2 study of single-agent zanubrutinib in patients with relapsed/refractory marginal zone lymphoma Three-year follow-up of treatment-naive and previously treated patients with Waldenstrom macroglobulinemia (WM) recieving single agent zanubrutinib Tislelizumab (BGB-A317) for relapsed/refractory extranodal NK/T-cell lymphoma: preliminary efficacy and safety results from a phase 2 study Tislelizumab (BGB-A317) for relapsed/refractory peripheral T-cell lymphomas: safety and efficacy results from a phase 2 study Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type Waldenstrom macroglobulinemia

ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM)

A phase 3, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma who are ineligible for stem cell transplantation Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma Phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer Trial in progress: a phase 2, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated B-cell malignancies Intolerant to prior treatment with ibrutinib or acalabrutinib ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: a phase 1B/2 trial-in-progress Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow‑up

ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM) Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma BGB-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC) Phase 3 study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC) Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib Trial in progress: A phase III, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL) Trial in progress: a phase II, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88^WT) Waldenström macroglobulinemia (WM) ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress. Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase II, single-arm, multicenter, study

Cost minimization analysis of zanubrutinib for the treatment of adult patients with mantle cell lymphoma who have recieved at least one prior therapy from the payers perspective in the United States Development of a novel conceptual model to describe the patient reported impact of living with non-small cell lung cancer